Compare Medpace Holdings Inc (MEDP) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Xylem, Inc. — how do they compare? Medpace Holdings Inc trades at $531.97 (market cap $15.08B), while Xylem, Inc. trades at $118.01 (market cap $28.67B). The key difference: Xylem, Inc. is the larger of the two by market cap, and Xylem, Inc. pays a 1.43% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | XYL | |
|---|---|---|
Market Cap | $15.08B | $28.67B |
Sector | Technology | Industrials |
52-Week High | $620.59 | $152.95 |
52-Week Low | $308.88 | $106.34 |
Enterprise Value | $14.55B | $29.92B |
Dividend Yield | — | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Xylem (XYL) trades at $120.64, down 1.74% over 24 hours, with a bullish technical signal from moving averages and strong support near $118. The company reported consistent earnings beats, with Q1 2026 EPS of $1.12 exceeding the $1.08 estimate, and revenue growth from $5.5B in 2022 to $9.04B in 2025. Recent developments include a partnership with Gross-Wen Technologies and leadership appointments, reinforcing its position in water solutions.
Outlook remains positive with a consensus price target of $153, implying 27% upside, though risks include execution of growth initiatives and macroeconomic pressures on industrial demand. The stock offers a dividend yield supported by 16 consecutive years of increases, appealing for long-term investors seeking water infrastructure exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
